FDA rejects The Medicines' cangrelor; but could have been worse
This article was originally published in Scrip
Executive Summary
Given the negative outcome of the February FDA advisory committee meeting, investors appeared not too surprised the agency ended up rejecting both indications for The Medicines Company's (MDCO) intravenous antiplatelet agent cangrelor, with shares of the firm losing only about 2% in morning trading on 1 May.